Federal approval of new drugs to treat the hepatitis C virus (HCV) represents "a dramatic, positive development for patients," says University at Buffalo liver disease expert Andrew H. Talal, MD. In October, the U.S. Food and Drug Administration approved the first HCV treatments that cure patients without interferon.
Hepatitis C in the News Your source for hepatitis C-related news from around the web.
Not sure what to submit? Read our news guidelines first.
— Heavier people might be more prone to liver cancer, insulin problems, researchers say.
— New study echoes prior findings and suggests caffeine isn't the key ingredient in the effect.
— Broader organ sharing in U.S. will result in more air travel, researchers say.
All over the country, state governments are grappling with the same question: "What do we do about Sovaldi?" The drug seems to be far more effective than alternatives at treating hepatitis C, a disease that, left untreated, frequently progresses to liver disease and then death. It also costs $84,000 for…
— Researchers conclude Sovaldi is cost-effective.
— Combination pill, taken once a day, blocks enzymes that virus needs to multiply.
The drug simeprevir (trade name: Olysio) has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in…
Hepatology | The World Hepatitis Alliance has created HCV Quest, a global survey that provides a forum for patients with hepatitis C virus, according to an announcement on the European Association for the Study of the Liver website.
Eliminating hepatitis C virus infection is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities, an expert argues. More than 185 million people worldwide, 3 percent of the world's population, are living with HCV and 350,000 die each year.